Sofosbuvir: A review of its use in patients with chronic hepatitis C

Drugs

Volumn 74, Issue 10, 2014, Pages 1127-1146

  Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; SOFOSBUVIR; VIRUS RNA; ANTIVIRUS AGENT; ENZYME INHIBITOR; NS-5 PROTEIN, HEPATITIS C VIRUS; URIDINE PHOSPHATE; VIRUS PROTEIN;

ABNORMAL LABORATORY RESULT; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG INTERACTION; DRUG METABOLISM; DRUG TOLERABILITY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIMIT OF QUANTITATION; LIVER TRANSPLANTATION; MIXED INFECTION; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRODUCTIVITY; RECURRENT INFECTION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; HEPATITIS C, CHRONIC; METABOLISM;

HEPATITIS C VIRUS;

ANTIVIRAL AGENTS; ENZYME INHIBITORS; HEPATITIS C, CHRONIC; HUMANS; URIDINE MONOPHOSPHATE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84903903987     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0247-z     Document Type: Article

References (68)

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60(2):392-420.
2. Dugum M, O'Shea R. Hepatitis C virus: here comes all-oral treatment. Cleve Clin J Med. 2014;81(3):159-72.
3. World Health Organization. Hepatitis C: fact sheet no. 164. 2014. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed 10 Apr 2014.
4. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-74.
5. Mariño Z, van Bömmel F, Forns X, et al. New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C. Gut. 2014;63(2):207-15.
6. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433-44.
7. Pockros PJ. Interferon-free hepatitis C therapy: how close are we? Drugs. 2012;72(14):1825-31.
8. Stedman CAM. Current prospects for interferon-free treatment of hepatitis C in 2012. J Gastroenterol Hepatol. 2013;28(1):38-45.
9. Wendt A, Adhoute X, Castellani P, et al. Chronic hepatitis C: future treatment. Clin Pharmacol. 2014;6:1-17.
10. American Association for the Study of Liver Diseases and Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. 2014. http://www.hcvguidelines.org/full-report-view. Accessed 10 Apr 2014.
11. European Medicines Agency. Sovaldi (sofosbovir): EU summary of product characteristics. 2014. http://www.ema.europa.eu/. Accessed 31 Mar 2014.
12. Gilead Sciences Inc. Sovaldi™ (sofosbuvir) tablets, for oral use: US prescribing information. 2013. http://www.sovaldi.com/. Accessed 31 Mar 2014.
13. Babusis DM, Curry MP, Denning JM, et al. Nucleotide analog levels in liver explants from HCV infected subjects undergoing liver transplantation after up to 24 weeks sofosbuvir (GS-7977) with ribavirin treatment [abstract no. 1091]. Hepatology. 2013;58(4 Suppl):737A.
14. Hebner C, Lee Y-J, Han B, et al. In vitro pan-genotypic and combination activity of sofosbuvir (GS-7977) in stable replicon cell lines [abstract no. 1875]. Hepatology. 2012;56(4 Suppl):1066A.
15. Svarovskaia ES, Dvory HS, Hebner C, et al. No resistance detected in four phase 3 clinical studies in HCV genotype 1-6 of sofosbuvir + ribavirin with or without peginterferon [abstract no. 1843]. Hepatology. 2013;58(4 Suppl):1091A-2A.
16. Svarovskaia ES, Dvory-Sobol H, Gontcharova V, et al. Comprehensive resistance testing in patients who relapsed after treatment with sofosbuvir (GS-7977)-containing regimens in phase 2 studies [abstract no. 753]. Hepatology. 2012;56(4 Suppl):551A.
17. Han B, Mo H, Wong KA. In vitro analyses of HCV NS5B S282T mutants in multiple HCV genotypes show low levels of reduced susceptibility to sofosbuvir (GS-7977), no cross resistance to other classes of direct-acting antivirals, and hypersensitivity to ribavirin [abstract no. 1078]. Hepatology. 2012;56(4 Suppl):711A-2A.
18. Rajyaguru S, Xu S, Hebner C, et al. Sofosbuvir selects the NS5B S282T mutation in vitro in genotype 1-6 replicons and is not cross-resistant to resistance associated variants selected by other classes of antiviral inhibitors [abstract no. 1094]. Hepatology. 2013;58(4 Suppl):739A.
19. Naggie S, Sulkowski M, Lalezari J, et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2 and 3 infection in patients coinfected with HIV (PHOTON-1) [abstract no. 26 plus slide presentation]. In: Conference on Retroviruses and Opportunistic Infections 2014, 3-6 Mar 2014.
20. Guedj J, Pang PS, Denning J, et al. Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938. Antivir Ther. 2014;19(2):211-20.
21. European Medicines Agency. Sovaldi (sofosbuvir): EU public assessment report. 2014. http://www.ema.europa.eu/. Accessed 10 Apr 2014.
22. Osinusi A, Meissner EG, Lee Y-J, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013;310(8):804-11.
23. Meissner EG, Bon D, Prokunina-Olsson L, et al. IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis. 2014;209(11):1700-4.
24. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878-87.
25. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867-77.
26. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370(21):1993-2001.
27. Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013;381(9883):2100-7.
28. Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2013;13(5):401-8.
29. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368(1):34-44.
30. Tong X, Le Pogam S, Li L, et al. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J Infect Dis. 2014;209(5):668-75.
31. Kirby B, Gordi T, Symonds WT, et al. Population pharmacokinetics of sofosbuvir and its major metabolite (GS-331007) in healthy and HCV infected adult subjects [abstract no. 1106]. Hepatology. 2013;58(4 Suppl):746A-7A.
32. Kirby B, Mathias A, Rossi S, et al. No clinically significant pharmacokinetic drug interactions between sofosbuvir (GS-7977) and HIV antiretrovirals Atripla®, rilpivirine, darunavir/ritonavir, or raltegravir in healthy volunteers [abstract no. 1877]. Hepatology. 2012;56(4 Suppl):1067A.
33. Mathias A, Cornpropst M, Clemons D, et al. No clinically significant pharmacokinetic drug-drug interactions between sofosbuvir (GS-7977) and the immunosuppressants, cyclosporine A or tacrolimus in healthy volunteers [abstract no. 1869]. Hepatology. 2012;56(4 Suppl):1063A-4A.
34. German P, Moorehead L, Pang PS, et al. Lack of a clinically important pharmacokinetic interaction between norgestimate/ethinyl estradiol and sofosbuvir (SOF) or ledipasvir (LDV) in HCV-uninfected female subjects [abstract no. 469]. Hepatology. 2013;58(4 Suppl):433A.
35. German P, Mathias A, Pang PS, et al. Lack of a clinically significant pharmacokinetic drug-drug interaction between sofosbuvir (GS-7977) and GS-5885 or GS-9669 in healthy volunteers [abstract no. 1888]. Hepatology. 2012;56(4 Suppl):1072A-3A.
36. Mogalian E, German P, Brainard DM, et al. Lack of a clinically significant pharmacokinetic drug-drug interaction between sofosbuvir and GS-5816 in healthy volunteers [abstract no. 465]. Hepatology. 2013;58(4 Suppl):431A.
37. Lawitz E, Poordad F, Brainard DM, et al. Sofosbuvir in combination with PegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment-experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study [abstract no. LB-4]. Hepatology. 2013;58(6 Suppl):1380A.
38. Curry MP, Forns X, Chung R, et al. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation [slide presentation]. In: Asia Pacific Association for the Study of the Liver 2014, 12-15 Mar 2014, Brisbane.
39. Lawitz E, Wyles D, Gordon S, et al. 12 weeks of treatment with sofosbuvir + peginterferon + ribavirin achieves 90% SVR in treatment-naive genotype 1, 4, 5, and 6 HCV-infected patients: results of the NEUTRINO study [slide presentation]. In: 23rd Conference of the Asian Pacific Association for the Study of the Liver 2013, Jun 6-9 2013, Singapore.
40. Wyles DL, Nelson DR, Swain MG, et al. On treatment HCV RNA as a predictor of virologic response in sofosbuvir-containing regimens for genotype 2/3 HCV infection: analysis of the FISSION, POSITRON, and FUSION studies [abstract no. 1112]. Hepatology. 2013;58(4 Suppl):750A.
41. Zeuzem S, Dusheiko GM, Colombo M, et al. Early viral kinetics do not predict treatment outcome with sofosbuvir + ribavirin for 12 or 24 weeks in HCV genotype 2/3 patients in the VALENCE trial [abstract no. P1119]. In: 49th Annual Meeting of the European Association for the Study of the Liver, 9-13 Apr 2014, London.
42. Yoshida EM, Sulkowski MS, Gane EJ, et al. The concordance between SVR4, SVR12, and SVR24 in patients with chronic HCV infection who received treatment with sofosbuvir in phase 3 clinical trials [abstract no. 1087]. Hepatology. 2013;58(4 Suppl):734A.
43. Patel K, Gordon SC, Sheikh AM, et al. Efficacy and safety of sofosbuvir in patients according to fibrosis stage: an analysis of phase 3 data [abstract no 1093]. Hepatology. 2013;58(4 Suppl):738A-9A.
44. Foster GR, Strasser S, Christensen C, et al. Sofosbuvir-based regimens are associated with high SVR rates across genotypes and among patients with multiple negative predictive factors [abstract no. 066 plus slide presentation]. In: 49th Annual Meeting of the European Association for the Study of the Liver, 9-13 Apr 2014, London.
45. Younossi ZM, Stepanova M, Henry L, et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol. 2014;60(4):741-7.
46. Younossi ZM, Stepanova M, Henry L, et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2013;. doi: 10.1016/j.cgh.2013.11.032.
47. Gordon S, Towner W, Aggarwal A, et al. Integrated safety analysis of sofosbuvir-based HCV treatment regimens from phase 3 studies [abstract no. P1171 plus poster]. In: 49th Annual Meeting of the European Association for the Study of the Liver, 9-13 Apr 2014, London.
48. Naggie S, Sulkowski M, Gaggar A, et al. The impact of HIV co-infection on rates and severity of anemia occurring during treatment with sofosbuvir-containing HCV regimens: a pooled analysis [abstract no. P1173 plus poster]. In: 49th Annual Meeting of the European Association for the Study of the Liver, 9-13 Apr 2014, London.
49. European Association for the Study of the Liver. EASL recommendations of treatment of hepatitis C 2014. 2014. http://www.easl.eu. Accessed 24 Apr 2014.
50. Cheng W, Shafran S, Beavers K, et al. Long term follow-up of patients treated with sofosbuvir in the phase 3 studies FISSION, POSITRON, FUSION and NEUTRINO [abstract no. P1112 plus poster]. In: 49th Annual Meeting of the European Association for the Study of the Liver, 9-13 Apr 2014, London.
51. Vertex Pharmaceuticals Incorporated. Incivek® (telaprevir) tablets, for oral use: US prescribing information. 2013. http://www.incivek.com/. Accessed 10 Apr 2014.
52. Merck & Co Inc. Victrelis® (boceprevir) capsules for oral use: US prescribing information. 2014. http://www.victrelis.com. Accessed 10 Apr 2014.
53. Mangia A, Kugelmas M, Everson GT, et al. Virologic response rates to sofosbuvir-containing regimens are similar in patients with and without traditional negative predictive factors: a retrospective analysis of phase 3 data [abstract no. 1115]. Hepatology. 2013;58(4 Suppl):752A-3A.
54. Esteban R, Nyberg L, Lalezari J, et al. Successful retreatment with sofosbuvir-containing regimens for HCV genotype 2 or 3 infected patients who failed prior sofosbuvir plus ribavirin therapy [abstract no. 08]. In: 49th Annual Meeting of the European Association for the Study of the Liver, 9-13 Apr 2014, London.
55. Gane EJ, Stedman CA, Hyland RH, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology. 2014;146(3):736-43.e1.
56. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383(9916):515-23.
57. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889-98.
58. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483-93.
59. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879-88.
60. Gilead Sciences Inc. Gilead announces U.S. FDA priority review designation for ledipasvir/sofosbuvir fixed-dose combination tablet for chronic hepatitis C genotype 1 infection [media release]. 2014. http://www.gilead.com. Accessed 10 Apr 2014.
61. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP): final minutes for the meeting held on 17-20 February 2014. 2014. http://www.ema.europa.eu. Accessed 14 Apr 2014.
62. Jacobsen IM, Ghalib RH, Rodriguez-Torres M, et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study [abstract no. LB-3]. Hepatology. 2013;58(6 Suppl):1379A.
63. Janssen. Olysio (simeprevir) capsules, for oral use. 2013. http://www.olysio.com/. Accessed 10 Apr 2014.
64. European Medicines Agency. Olysio (simeprevir): EU summary of product characteristics. 2014. http://www.ema.europa.eu/. Accessed 28 May 2014.
65. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211-21.
66. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl. 2008;14(10 Suppl 2):S36-44.
67. Samuel D, Charlton MR, Gane E, et al. Sofosbuvir and ribavirin for the treatment of recurrent hepatitis C infection after liver transplantation: results of a prospective, multicenter study [abstract no. P1232]. In: 49th Annual Meeting of the European Association for the Study of the Liver, 9-13 Apr 2014, London.
68. Forns X, Fontana RJ, Moonka D, et al. Initial evaluation of the sofosbuvir compassionate use program for patients with severe recurrent HCV following liver transplantation [abstract no. 1084]. Hepatology. 2013;58(4 Suppl):732A-3A.